Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib.

Adult Aged Aged, 80 and over Antineoplastic Agents / therapeutic use Biomarkers, Tumor / genetics Female Fusion Proteins, bcr-abl / antagonists & inhibitors Humans Imatinib Mesylate / therapeutic use Leukemia, Myelogenous, Chronic, BCR-ABL Positive / drug therapy Male Middle Aged Protein Kinase Inhibitors / therapeutic use RNA, Messenger / genetics Treatment Outcome
BCR-ABL1 European Leukemia Net chronic myeloid leukemia early molecular response imatinib mesylate

Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
06 May 2019
Historique:
received: 23 03 2019
revised: 01 05 2019
accepted: 02 05 2019
entrez: 9 5 2019
pubmed: 9 5 2019
medline: 21 8 2019
Statut: epublish

Résumé

A reduction in

Identifiants

DOI: 10.3390/ijms20092226 PMID: 31064152 PMC: PMC6539817
pubmed: 31064152
pii: ijms20092226
doi: 10.3390/ijms20092226
pmc: PMC6539817
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
BCR-ABL1 fusion protein, human 0
Biomarkers, Tumor 0
Protein Kinase Inhibitors 0
RNA, Messenger 0
Imatinib Mesylate 8A1O1M485B
Fusion Proteins, bcr-abl EC 2.7.10.2

Types de publication

Journal Article

Langues

eng

Références

Nat Rev Cancer. 2005 Mar;5(3):172-83
pubmed: 15719031
Blood. 2006 Jul 1;108(1):28-37
pubmed: 16522812
Blood. 2006 Aug 15;108(4):1370-3
pubmed: 16627755
N Engl J Med. 2006 Dec 7;355(23):2408-17
pubmed: 17151364
Leukemia. 2008 Jan;22(1):96-102
pubmed: 17943168
Int J Cancer. 2009 Jun 1;124(11):2539-48
pubmed: 19173293
Acta Oncol. 2010 May;49(4):506-8
pubmed: 20331405
PLoS One. 2011 Feb 11;6(2):e17020
pubmed: 21347248
Blood. 2011 Jul 21;118(3):686-92
pubmed: 21536864
Acta Haematol. 2011;126(4):205-10
pubmed: 21934293
Acta Haematol. 2012;127(1):7-9
pubmed: 21986290
J Clin Oncol. 2012 Jan 20;30(3):232-8
pubmed: 22067393
Leukemia. 2012 Sep;26(9):2096-102
pubmed: 22446502
Leukemia. 2012 Oct;26(10):2172-5
pubmed: 22504141
Blood. 2012 Jul 12;120(2):291-4
pubmed: 22645182
Blood. 2013 Apr 4;121(14):2739-42
pubmed: 23380743
Mol Cancer Ther. 2013 Jun;12(6):1085-98
pubmed: 23536723
Leukemia. 2013 Oct;27(10):2016-22
pubmed: 23752173
Blood. 2013 Aug 8;122(6):872-84
pubmed: 23803709
FASEB J. 2014 Mar;28(3):1221-36
pubmed: 24297701
Carcinogenesis. 2014 May;35(5):1132-43
pubmed: 24445143
Am J Hematol. 2014 Jun;89(6):626-32
pubmed: 24619861
Rev Bras Hematol Hemoter. 2015 Mar-Apr;37(2):142-3
pubmed: 25818829
Leukemia. 2016 Jan;30(1):48-56
pubmed: 26416462
PLoS One. 2015 Oct 16;10(10):e0140585
pubmed: 26473951
Curr Cancer Drug Targets. 2016;16(7):594-605
pubmed: 26728039
Expert Rev Anticancer Ther. 2016;16(3):273-8
pubmed: 26852913
Leukemia. 2016 Jul;30(7):1493-501
pubmed: 27044711
Leukemia. 2016 Aug;30(8):1638-47
pubmed: 27133824
Nat Rev Clin Oncol. 2017 Mar;14(3):141-154
pubmed: 27752053
N Engl J Med. 2017 Mar 9;376(10):917-927
pubmed: 28273028
Clin Cancer Res. 2017 Dec 1;23(23):7189-7198
pubmed: 28928163
Mol Cancer. 2018 Feb 19;17(1):56
pubmed: 29455672
Medchemcomm. 2017 Feb 16;8(5):841-854
pubmed: 30108801
Cancer. 1988 Apr 1;61(7):1441-6
pubmed: 3162181
Blood. 1984 Apr;63(4):789-99
pubmed: 6584184

Auteurs

Stefania Stella (S)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. stefania.stel@gmail.com.
Center of Experimental Oncology and Hematology, A.O.U. Policlinico Vittorio Emanuele, 95123 Catania, Italy. stefania.stel@gmail.com.

Valentina Zammit (V)

Division of Hematology and Bone Marrow Transplant, AOU Policlinico - V. Emanuele, 95123 Catania, Italy. valentina.zammit@tiscali.it.

Silvia Rita Vitale (SR)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. silviarita.vitale@gmail.com.
Center of Experimental Oncology and Hematology, A.O.U. Policlinico Vittorio Emanuele, 95123 Catania, Italy. silviarita.vitale@gmail.com.

Maria Stella Pennisi (MS)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. perny76@gmail.com.
Center of Experimental Oncology and Hematology, A.O.U. Policlinico Vittorio Emanuele, 95123 Catania, Italy. perny76@gmail.com.

Michele Massimino (M)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. michedot@yahoo.it.
Center of Experimental Oncology and Hematology, A.O.U. Policlinico Vittorio Emanuele, 95123 Catania, Italy. michedot@yahoo.it.

Elena Tirrò (E)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. ele_tir@yahoo.it.
Center of Experimental Oncology and Hematology, A.O.U. Policlinico Vittorio Emanuele, 95123 Catania, Italy. ele_tir@yahoo.it.
ORCID: 0000-0001-8012-5134

Stefano Forte (S)

Mediterranean Institute of Oncology, 95029 Viagrande, Italy. stefano.forte@grupposamed.com.
ORCID: 0000-0001-5746-7451

Antonio Spitaleri (A)

Division of Hematology and Bone Marrow Transplant, AOU Policlinico - V. Emanuele, 95123 Catania, Italy. dottspitaleriantonio@gmail.com.

Agostino Antolino (A)

Department of Transfusional Medicine, Maria Paternò-Arezzo Hospital, 97100 Ragusa, Italy. agostino.antolino@asp.rg.it.

Sergio Siracusa (S)

Division of Hematology, A.O.U. Policlinico "P. Giaccone", University of Palermo, 90127 Palermo, Italy. sergio.siragusa@unipa.it.

Vincenzo Accurso (V)

Division of Hematology, A.O.U. Policlinico "P. Giaccone", University of Palermo, 90127 Palermo, Italy. casteldaccia@tiscali.it.

Donato Mannina (D)

Division of Hematology, Papardo Hospital, 98158 Messina, Italy. donamanni@gmail.com.

Stefana Impera (S)

Division of Oncology and Hematology, ARNAS Garibaldi-Nesima, 95122 Catania, Italy. st.impera@alice.it.

Caterina Musolino (C)

Division of Hematology, University of Messina, 98125 Messina, Italy. cmusolino@unime.it.

Sabina Russo (S)

Division of Hematology, University of Messina, 98125 Messina, Italy. sabinarusso@tiscali.it.

Alessandra Malato (A)

Division of Hematology and Bone Marrow Transplant, Villa Sofia-Cervello Hospital, 90146 Palermo, Italy. alessandramalato@hotmail.com.

Giuseppe Mineo (G)

Division of Hematology, San Vincenzo Hospital, 98039 Taormina, Italy. giuseppe.mineo65@tiscali.it.

Maurizio Musso (M)

Division of Hematology, La Maddalena Hospital, 90146 Palermo, Italy. mamusso@libero.it.

Ferdinando Porretto (F)

Division of Hematology, La Maddalena Hospital, 90146 Palermo, Italy. fporretto@alice.it.

Bruno Martino (B)

Hematology Department, Grande Ospedale Metropolitano, Reggio Calabria, 89124 Reggio Calabria, Italy. brunmartin@libero.it.

Francesco Di Raimondo (F)

Division of Hematology and Bone Marrow Transplant, AOU Policlinico - V. Emanuele, 95123 Catania, Italy. diraimon@unict.it.
Department of Surgery, Medical and Surgical Specialities, University of Catania, 95123 Catania, Italy. diraimon@unict.it.

Livia Manzella (L)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. manzella@unict.it.
Center of Experimental Oncology and Hematology, A.O.U. Policlinico Vittorio Emanuele, 95123 Catania, Italy. manzella@unict.it.

Paolo Vigneri (P)

Department of Clinical and Experimental Medicine, University of Catania, 95123 Catania, Italy. vigneripaolo@gmail.com.
Center of Experimental Oncology and Hematology, A.O.U. Policlinico Vittorio Emanuele, 95123 Catania, Italy. vigneripaolo@gmail.com.

Fabio Stagno (F)

Division of Hematology and Bone Marrow Transplant, AOU Policlinico - V. Emanuele, 95123 Catania, Italy. fsematol@tiscali.it.
ORCID: 0000-0002-7947-158X

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Clinical Implications of Discordant Early...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Clinical Implications of Discordant Early...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Sujet âgé › Sujet âgé de 80 ans ou plus › Clinical Implications of Discordant Early...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › Clinical Implications of Discordant Early...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Clinical Implications of Discordant Early...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines tumorales › Protéines oncogènes › Protéines proto-oncogènes › Protéines proto-oncogènes c-bcr › Protéines de fusion bcr-abl › Clinical Implications of Discordant Early...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinical Implications of Discordant Early...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyrimidines › Mésilate d'imatinib › Clinical Implications of Discordant Early...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Caractéristiques de la maladie › Maladie chronique › Leucémie myéloïde chronique BCR-ABL positive › Clinical Implications of Discordant Early...
questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Adulte d'âge moyen › Clinical Implications of Discordant Early...
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Mécanismes moléculaires de l'action pharmacologique › Antienzymes › Inhibiteurs de protéines kinases › Clinical Implications of Discordant Early...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN messager › Clinical Implications of Discordant Early...
questionsmedicales.fr › Qualité, accès, évaluation des soins de santé › Qualité des soins de santé › Mécanismes d'évaluation des soins de santé › Évaluation des résultats et des processus en soins de santé › Évaluation de résultat (soins) › Résultat thérapeutique › Clinical Implications of Discordant Early...